M. N. Sadovskaya

M. N. Sadovskaya

Auto-generated profile, based on publicly available information

M. N. Sadovskaya

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
OGOlga Goronkova
Olga Goronkova
GNGalina Novichkova
Galina Novichkova
TSTatiana Salimova
Tatiana Salimova
IKIrina Kalinina
Irina Kalinina
DBDina Baidildina
Dina Baidildina
AMAlexey Maschan
Alexey Maschan
We compared the efficacy and safety of eltrombopag (ELTR) combined with immunosuppressive therapy (IST) and IST alone in treatment-naïve children with severe (SAA) and very severe (vSAA) aplastic anemia. Ninety-eight pediatric patients were randomized to receive horse antithymocyte globulin (hATG) and cyclosporin A (CsA) with (n = 49) or without (n = 49) ELTR. The primary endpoint was the overall response rate (ORR) at 4 months. After 4 months, nonresponders were crossed over to the alternative group. In all patients, the ORR in ELTR + IST and IST groups was similar (65% vs 53%; P = .218); however, the complete response (CR) rate was significantly higher in the ELTR + IST group (31% vs 12%; P = .027). In severity subgroups, the ORR was 89% vs 57% (P = .028) in favor of IST + ELTR in SAA, but it did not differ in patients with vSAA (52% vs 50%; P = .902). At 6 months after the crossover, 61% of initial ELTR(−) patients achieved a response compared with 17% of initial ELTR(+) patients (P = .016). No significant difference in ELTR + IST and IST groups was observed in the 3-year overall survival (OS) (89% vs 91%; P = .673) or the 3-year event-free survival (EFS) (53% vs 41%; P = .326). There was no unexpected toxicity related to ELTR. Adding ELTR to standard IST was well tolerated and increased the CR rate. The greatest benefit from ELTR combined with IST was observed in patients with SAA but not in those with vSAA. The second course of IST resulted in a high ORR in initial ELTR(−) patients who added ELTR and had limited efficacy among patients who received ELTR upfront. This trial was registered at Clinicaltrials.gov as #NCT03413306.

27 March 2022 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
IKI. I. Kalinina
I. I. Kalinina
DVD. A. Venyov
D. A. Venyov
YOYu. V. Olshanskaya
Yu. V. Olshanskaya
MSM. N. Sadovskaya
M. N. Sadovskaya
OGO. V. Goronkova
O. V. Goronkova
ЮОЮ. В. Ольшанская
Ю. В. Ольшанская
Over the past years, the outcomes of patients with acute myeloid leukemia (AML) have significantly improved due to the use of intensive chemotherapy, more effective supportive therapy, and the availability of allogeneic hematopoietic stem cell transplantation. This article presents the outcomes of children with AML treated in accordance with the AML-MM-2006 protocol. Our study was approved by the Independent Ethics Committee of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The study included 233 patients with a median age of 6.5 years (7 days – 18 years) who were stratified into the following risk groups: standard risk, intermediate risk, and high risk. The 5-year event-free survival (EFS) was 0.64 ± 0,14, 0.49 ± 0.05, and 0.43 ± 0.05 for standard-risk (n = 12), intermediate-risk (n = 106), and high-risk (n = 115) patients, respectively (p = 0.14), while the 5-year overall survival (OS) was 1.0 year, 0.7 ± 0.05 and 0.55 ± 0.05, respectively (p = 0.001). The OS in the entire cohort was 0.68 ± 0.032. Factors associated with poor prognosis included hyperleukocytosis, the presence of extramedullary lesions, and age 1 year. The overall survival rates in these patient groups were 0.55 ± 0.08, 0.39 ± 0.09 and 0.49 ± 0.08, respectively. The worst prognosis was for patients with monosomy 7 and t(7;12) whose OS rates were 0.25 ± 0.2 and 0.4 ± 0.2, respectively. For non-responders and patients with relapsed AML, the OS was 0.33 ± 0.08 and 0.54 ± 0.06, respectively. Early death (before remission could be achieved) occurred in 4% of patients, and 3.8% of patients died in first remission. Sixtytwo percent of deceased patients died of disease progression. In the entire cohort of patients, the five-year EFS was 0.53 ± 0.047, the cumulative risk of relapse after 3 years of remission was 40%, the confidence interval was 23–89%.

27 March 2020 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
ESE. V. Suntsova
E. V. Suntsova
ICI. I. Chikvina
I. I. Chikvina
MSM. N. Sadovskaya
M. N. Sadovskaya
NKN. N. Kotskaya
N. N. Kotskaya
LHL. A. Hachatryan
L. A. Hachatryan
GNG. A. Novichkova
G. A. Novichkova
Immune thrombocytopenia (ITP) is a disease with a heterogeneous clinical manifestation. In the majority of children newly diagnosed ITP is a self-limited benign disorder, while chronic ITP develops rarely. The clinical onset of ITP can occur in very different ways: from nearly invisible skin hemorrhage to severe life-threatening bleeding. Conventional treatments promote a response in most patients, but in a small number of children thrombocytopenia is unresponsive. In this article, we describe our experience of the clinical use of romiplostim in children with severe unresponsive newly diagnosed ITP. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. The severity of bleeding decreased significantly after the start of romiplostim therapy in all cases. Durable complete (platelets 100 × 109 /l) response was achieved in five out of six patients 4 to 8 weeks after starting therapy. Three children have remained in lasting remission for 1 to 3 years after the discontinuation of romiplostim. There were no adverse events associated with romiplostim.

8 April 2025 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
IKI. I. Kalinina
I. I. Kalinina
DVD. A. Venyov
D. A. Venyov
MSM. N. Sadovskaya
M. N. Sadovskaya
YSYu. V. Starichkova
Yu. V. Starichkova
KVK. A. Voronin
K. A. Voronin
MMMichael Maschan
Michael Maschan
We conducted a prospective observational registry study at the Dmitry Rogachev National Medical Research Center aiming to evaluate acute myeloid leukemia (AML) treatment and its outcomes in children in regional oncology/hematology centers of Russia as well as to report the results. The study was approved by the Independent Ethics Committee and the Scientific Council of the The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. We enrolled a total of 380 patients (205 boys and 175 girls) with newly diagnosed AML with the median age of 6.6 years (52 days to 18 years) and the median white blood cell count at disease onset equaling 17.7 (0–540) × 109/L. Fifty-two patients (13.6%) had WBC count greater than 100 × 109/L (hyperleukocytosis), 55 patients (14%) presented with neuroleukemia, and 60 (16%) had extramedullary lesions. The enrolled patients were stratified into a standard risk (92 patients), intermediate risk (99) or high risk (189) group. The first clinical and hematological remission (CR1) was achieved in 324 patients (85%), with early mortality rate reaching 8.4%. The median follow-up of the survivors was 8.3 years (1.5 months to 11.5 years). The 5-year overall survival (OS) in the entire cohort was 0.60 ± 0.025, the 5-year event-free survival (EFS) – 0.42 ± 0.025, and the cumulative incidence of relapse (CIR) – 0.37 ± 0.027. Initial extramedullary lesions (OS 0.47 ± 0.06 and EFS 0,37 ± 0.06) and hyperleukocytosis (OS 0.47 ± 0.07 and EFS 0.25 ± 0.06) led to a poorer prognosis in the AML patients, but CIR was not affected by these factors. The lowest OS rate was observed in the patients with monosomy 7 and with t(10;11)(p11-15;q21)/PICALM::MLLT10, totaling 0.2 ± 0.2 and 0.14 ± 0.1, respectively. Hematologic stem cell transplantation (HSCT) performed in CR1 significantly improved OS (0.84 ± 0.05), EFS (0.77 ± 0.06) and CIR (0.18 ± 0.05) in the high-risk patients. The majority of allogeneic HSCTs were performed using cells from haploidentical (51%), unrelated (25%) and genoidentical donors (18%). In the 50 patients treated with HSCT while in active disease, the OS was 50%. Out of 189 high-risk patients, only 67 (35%) underwent HSCT in CR1. The OS and EFS of the patients from regions were 0.51 ± 0.033 and 0.38 ± 0.032, respectively. The CIR was 0.36 ± 0,04. Relapses were reported in 37% of the patients who had achieved СR1. A total of 157 (41%) patients died during the study, out of which 112 patients had been treated at regional hospitals. The OS in the AML pediatric patients in Russia was 60%. The main treatment failures were toxic deaths (16%) and relapses (37%). In 2018, healthcare professionals of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology developed the AMLMRD-2018 protocol that could also be implemented in regional clinics, aiming to reduce toxic (infectious) death rates and thus increase the OS by at least 10% as well as to ensure HSCT accessibility for all high-risk patients.

7 October 2021 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
ESE. V. Suntsova
E. V. Suntsova
AMA. A. Maschan
A. A. Maschan
OMO. N. Mironenko
O. N. Mironenko
ДБД. Д. Байдильдина
Д. Д. Байдильдина
IKI. I. Kalinina
I. I. Kalinina
GNG. A. Novichkova
G. A. Novichkova
Thrombopoietin receptor agonists (TPO-RA) – romiplostim and eltrombopag – changed considerably the therapeutic options for severe persistent and chronic immune thrombocytopenia (ITP). The article presents the results of a retrospective study of TPO-RA efficacy and safety in patients under 18 years of age. The study was approved by the Independent Ethics Committee and Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Sixty-eight children had a total of 89 courses of TPO-RA (44 romiplostim and 45 eltrombopag). Their median age was 6.5 years. The median ITP duration was 15.8 months. All patients received previous ITP therapy (1–6 lines). Before the initiation of TPO-RA, the majority of patients had thrombocytopenia with bleeding. In most cases, the platelet response was achieved within the first 2 months of treatment. The average effective doses of romiplostim and eltrombopag were 10 mg/kg per week and 75 mg per day, respectively. Half of patients in romiplostim group and 62% of patients in eltrombopag group did not require extra therapy. The majority of patients (75.6–81.8%) achieved an overall response, but only near 50% achieved a durable (more than 24 weeks) platelet response. Six patients sustained the response after TPO-RA discontinuation. The most common adverse events (AE) of TPO-RA therapy were transient elevation in hepatic enzymes in eltrombopag group (28.9%) and thrombocytosis (18.2–22.2%) in both groups. In 6 cases the therapy was discontinued due to AEs. Two AEs were serious. Our results demonstrate that TPO-RA could safely increase platelet counts and decrease the risk of spontaneous life-threatening bleeding in nearly half of children with severe persistent and chronic ITP. TPO-RA could help to avoid long-term immunosuppressive therapy and splenectomy or delay them and the ITP remission is possible in some cases.

1 June 2023 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
AIA.K. Ignatova
A.K. Ignatova
OHOncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
IKI.I. Kalinina
I.I. Kalinina
DVD.A. Venyov
D.A. Venyov
DED.A. Evseev
D.A. Evseev
AMA.A. Maschan
A.A. Maschan
Infants of the first year of life represent a unique group of patients with acute myeloid leukemia (AML). Materials and methods of the research: the characteristics of 492 patients with newly diagnosed AML aged 10 DoL-18 y/o who received intensive chemotherapy according to the AML-MM-2006 and AML-MRD-2018 guidelines in Apr. 2007-Apr. 2021 were analyzed. The analysis was carried out separately for infants (/=3 y/o). Patients of the 1-3 y/o group were similar in morphological and cytogenetic characteristics to the infants’ group but had a smaller tumor mass and higher survival rates. The 5-year overall survival of infants was statistically significantly lower than in older patients, 52% vs. 67% (p<0.001), primarily due to high mortality prior to remission, which in its turn was caused by complications associated with hyperleukocytosis. Conclusions: given the vulnerability of this category of patients, it is reasonable to transfer them to larger medical facilities with extensive experience in the field in order to conduct the remission induction stage (especially cytoreduction) within the intensive care unit.